

 Early Warning System

EIB-20220948

PROJECT HIVE (IEU LS)



Quick Facts

Countries	Denmark
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	C
Voting Date	2023-12-21
Borrower	ZEALAND PHARMA A/S
Sectors	Education and Health, Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 99.06 million
Project Cost (USD)	\$ 374.22 million



Project Description

According to the Bank's website, the project supports the promoter's research activities to develop a diversified portfolio of novel preclinical and clinical-stage peptide-based medicinal products treating metabolic, gastrointestinal and rare diseases.

The aim is to support the development of various drug candidates with significant and detrimental social and economic cost. The project will also supports the development of drugs aimed at improving standard care for people living with rare diseases, whose medical needs are currently unmet.



Early Warning System Project Analysis

The project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environment, climate and social (ECS) information and based on the review of the likely significant ECS risks and impacts and the mitigation measures and management systems in place, the project is deemed to have low residual ECS risks and impact. No further sustainability proofing is required.



Investment Description

- European Investment Bank (EIB)

The loan will provide direct quasi-equity financing supported by the Invest EU mandate to finance RD&I activities of an innovative Danish biopharmaceutical for advancing the development of its diversified portfolio of novel preclinical and clinical-stage peptide-based drug-candidates targeted at rare diseases, metabolic, gastrointestinal and cardiovascular disorders.



Private Actors Description

Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. The company's head office is situated in Søborg near Copenhagen, and it has close to 200 employees.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	ZEALAND PHARMA A/S	Client	-



Contact Information

No contacts available at the time of disclosure.

Zealand Pharma A/S

Sydmarken 11

2860 Søborg

Denmark

Phone: +45 88 77 36 00

info@zealandpharma.com

Zealand Pharma U.S., Inc.

44 Farnsworth St

9th Floor

Boston, MA 02210

ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>



Bank Documents

- [Environmental and Social Data Sheet \(ESDS\) - PROJECT HIVE \(IEU LS\)](#)
- [PROJECT DATA SHEET\(S\): PROJECT HIVE \(IEU LS\)](#)

Media

- [Denmark: InvestEU - Zealand Pharma agrees €90 million financing deal with EIB to advance its research](#)